Dr. Bonventre is Chief of the Renal Unit and Director of the Bioengineering Division at Brigham and Women’s Hospital and has had a long-standing interest in various aspects of cellular injury and repair mechanisms in the kidney with a special emphasis on the role of inflammation, biomarkers and stem cells.... Read more about Joseph V. Bonventre, MD, PhD
The step-by-step differentiation of embryonic cells into different types of neurons lays the foundation for our sensory responses, motor commands, and cognitive behaviors. Our research explores such differentiation programs in mammals using a combination of genetic, embryological, and molecular biological methods. While the generation of such neural diversity is a complex process culminating in the most sophisticated of wiring circuits, one simplifying approach is to start by tracking the specification, differentiation, and migration paths taken by specific sets of cells originating from primitive neuroectoderm.... Read more about Susan Dymecki, MD, PhD
Dana-Farber Cancer Institute Brigham and Women's Hospital Harvard Medical School
Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used in the treatment of patients with hematologic malignancies, but continues to be associated with severe toxicities. Both the effectiveness and toxicity of HSCT are mediated by donor T-cells in the stem cell graft. Those T cells that target antigens expressed on recipient leukemia cells play an important role in eradicating residual tumor cells and preventing leukemia relapse after transplant. In contrast, T cells that target antigens expressed by normal tissues in the recipient are the primary mediators of graft versus host disease (GVHD) and thus lead to substantial toxicities. My laboratory focuses on the assessment of donor immune function after HSCT and characterization of the immune mechanisms responsible for graft versus leukemia (GVL) and GVHD.... Read more about Jerome Ritz, MD
Harvard Department of Stem Cell and Regenerative Biology Principal Faculty, Harvard Stem Cell Institute
Dr. Lee Rubin, co-leader of the HSCI Nervous System Diseases Program, has a broad experience in both academia and industry, particularly in the realms of cell-based assays and drug discovery. He received his PhD in neuroscience from the Rockefeller University and had postdoctoral training, also in Neuroscience, at Harvard Medical School and Stanford University School of Medicine.... Read more about Lee L. Rubin, Ph.D.
Co-chair, Harvard Department of Stem Cell and Regenerative Biology Senior Investigator, Islet Cell and Regenerative Biology, Joslin Diabetes Center
Stem cells are rare and unique cells capable of generating many different types of cells needed in the body. In adult tissues, different organs contain different stem cell populations, each of which produces a subset of the body's cells. For example, hematopoietic (blood-forming) stem cells generate all of the red and white blood cells needed to deliver oxygen to body tissues, fight infection, and stop bleeding. Similarly, myogenic (muscle-forming) stem cells generate mature muscle fibers necessary for controlled contraction of skeletal muscle. Work in the Wagers Lab focuses on understanding the mechanisms that regulate the function of these blood-forming and muscle-forming stem cells so that their potential can be optimally exploited for the treatment of diseases such as cancer, anemia, muscular dystrophy, and diabetes.... Read more about Amy Wagers, PhD